CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer - PubMed (original) (raw)
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
Mark J Smyth et al. J Immunol. 2006.
Abstract
CD4+CD25+ regulatory T cells (Treg) that suppress T cell-mediated immune responses may also regulate other arms of an effective immune response. In particular, in this study we show that Treg directly inhibit NKG2D-mediated NK cell cytotoxicity in vitro and in vivo, effectively suppressing NK cell-mediated tumor rejection. In vitro, Treg were shown to inhibit NKG2D-mediated cytolysis largely by a TGF-beta-dependent mechanism and independently of IL-10. Adoptively transferred Treg suppressed NK cell antimetastatic function in RAG-1-deficient mice. Depletion of Treg before NK cell activation via NKG2D and the activating IL-12 cytokine, dramatically enhanced NK cell-mediated suppression of tumor growth and metastases. Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity.
Similar articles
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L. Ghiringhelli F, et al. J Exp Med. 2005 Oct 17;202(8):1075-85. doi: 10.1084/jem.20051511. J Exp Med. 2005. PMID: 16230475 Free PMC article. - IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL. Takaki R, et al. J Immunol. 2005 Aug 15;175(4):2167-73. doi: 10.4049/jimmunol.175.4.2167. J Immunol. 2005. PMID: 16081783 - Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z, Guo L, Song Y, Zhang Y, Lin D, Hu B, Mei Y, Sandikin D, Liu H. Wang Z, et al. Cancer Immunol Immunother. 2017 Apr;66(4):537-548. doi: 10.1007/s00262-017-1959-1. Epub 2017 Feb 9. Cancer Immunol Immunother. 2017. PMID: 28184969 Free PMC article. - Control of NK cell functions by CD4+CD25+ regulatory T cells.
Ralainirina N, Poli A, Michel T, Poos L, Andrès E, Hentges F, Zimmer J. Ralainirina N, et al. J Leukoc Biol. 2007 Jan;81(1):144-53. doi: 10.1189/jlb.0606409. Epub 2006 Sep 7. J Leukoc Biol. 2007. PMID: 16959895 Review. - The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.
Ghiringhelli F, Ménard C, Martin F, Zitvogel L. Ghiringhelli F, et al. Immunol Rev. 2006 Dec;214:229-38. doi: 10.1111/j.1600-065X.2006.00445.x. Immunol Rev. 2006. PMID: 17100888 Review.
Cited by
- Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations.
Ge J, Yin X, Chen L. Ge J, et al. Front Immunol. 2024 Sep 3;15:1457189. doi: 10.3389/fimmu.2024.1457189. eCollection 2024. Front Immunol. 2024. PMID: 39290699 Free PMC article. Review. - The basic biology of NK cells and its application in tumor immunotherapy.
Jiang P, Jing S, Sheng G, Jia F. Jiang P, et al. Front Immunol. 2024 Aug 16;15:1420205. doi: 10.3389/fimmu.2024.1420205. eCollection 2024. Front Immunol. 2024. PMID: 39221244 Free PMC article. Review. - Lymphatic system regulation of anti-cancer immunity and metastasis.
Lei PJ, Fraser C, Jones D, Ubellacker JM, Padera TP. Lei PJ, et al. Front Immunol. 2024 Aug 15;15:1449291. doi: 10.3389/fimmu.2024.1449291. eCollection 2024. Front Immunol. 2024. PMID: 39211044 Free PMC article. Review. - A model of dysregulated crosstalk between dendritic, natural killer, and regulatory T cells in chronic obstructive pulmonary disease.
Mengistu DT, Curtis JL, Freeman CM. Mengistu DT, et al. Trends Immunol. 2024 Jun;45(6):428-441. doi: 10.1016/j.it.2024.04.010. Epub 2024 May 18. Trends Immunol. 2024. PMID: 38763820 - Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Godakhindi V, Tarannum M, Dam SK, Vivero-Escoto JL. Godakhindi V, et al. Adv Healthc Mater. 2024 Aug;13(20):e2400323. doi: 10.1002/adhm.202400323. Epub 2024 May 3. Adv Healthc Mater. 2024. PMID: 38653190 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials